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Purpose: Hepatic steatosis has been associated with some cardiovascular risks. Increased 
alanine aminotransferase (ALT) was suggested to be linked to endothelial dysfunction. We 
prospectively investigated the joint effect of hepatic steatosis and elevated ALT within the 
normal range on incident ischemic heart disease (IHD) risk as an extrahepatic complication.
Patients and Methods: We assessed 16,541 participants without diabetes using data from 
a health risk assessment study (HERAS) and Korean Health Insurance Review and Assessment 
(HIRA) data. We defined elevated ALT within the normal range as 30–40 IU/L in men and 23–40 
IU/L in women, according to previous Korean epidemiological data. We prospectively assessed 
hazard ratios (HRs) with 95% confidence intervals (CIs) for IHD using multivariate Cox 
proportional hazards regression models over a 50-month period after the baseline survey.
Results: During the follow-up period, 368 (2.2%) participants developed IHD. Compared to 
the group with no hepatic steatosis and controlled ALT, the HRs for IHD were 1.68 (95% CI, 
1.16–2.42) in the group with hepatic steatosis and elevated ALT after adjusting for con-
founding variables.
Conclusion: Hepatic steatosis and elevated ALT levels within the normal range may jointly 
affect the development of IHD among nondiabetic adults. This indicates that lifestyle advice 
and vascular health management should be recommended among individuals with hepatic 
steatosis and elevated ALT, even if it falls within the normal range.
Keywords: hepatic steatosis, alanine aminotransferase, prospective cohort study, ischemic 
heart disease, extrahepatic complication
Introduction
Hepatic steatosis is the marked accumulation of hepatic fat. The prevalence of 
excess liver fat has been gradually increasing, and it has been estimated that 
approximately 30% of adults worldwide have hepatic steatosis.1,2 This hepatic 
manifestation has been considered a benign condition associated with insulin 
resistance and metabolic syndrome.3,4 However, recent studies have demonstrated 
that patients with hepatic steatosis are at increased risk for ischemic heart disease 
(IHD) as an extrahepatic complication.5 Several studies have proposed that hepatic 
steatosis is also associated with coronary artery disease.6,7
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are 
circulating liver enzymes that represent liver damage. Of these liver enzymes, 
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ALT is more specific to the liver.8 In addition to hepatic 
complications, elevated ALT levels are associated with 
both systemic and hepatic insulin resistance.9,10 Previous 
studies have reported that elevated ALT is associated with 
endothelial dysfunction measured as brachial flow- 
mediated vasodilatation.10 Furthermore, this association 
was independent of insulin resistance, indicating contribut-
ing mechanisms in addition to insulin resistance.4,11
The upper limit of normal for ALT is considered to be 
approximately 40 IU/L in many laboratories, and elevated 
ALT is strongly associated with nonalcoholic fatty liver 
disease (NAFLD).12,13 Liver enzymes are normal in 
approximately 50% of patients with hepatic steatosis, and 
slightly increased ALT within the normal range was also 
shown to be associated with metabolic alterations.14 
Although there is a plausible combinatory effect of the 
two highly correlated hepatic manifestations on IHD, little 
is known about those joint influences on cardiovascular 
risks. Therefore, we prospectively investigated the joint 
effect of hepatic steatosis and elevated ALT within the 
normal range on incident IHD risk in a large-scale, com-




This study is based on health risk assessment study 
(HERAS) data that aimed to explore surrogate indicators 
for cardiovascular diseases (CVDs) among Korean adults. 
The study cohort consisted of 20,530 sequentially enrolled 
subjects who voluntarily visited the Health Promotion 
Centre, Gangnam Severance Hospital, Yonsei University 
College of Medicine, for a health examination between 
November 2006 and June 2010. Among the participants 
initially assessed, we excluded 1,590 (7.7%) participants 
with a history of IHD or ischemic stroke, a previous 
diagnosis of type 2 diabetes, or a fasting plasma glucose 
(FPG) level ≥ 126 mg/dL. Participants who met at least 
one of the following criteria were also excluded: younger 
than 20 years of age, ALT ≥ 40 IU/L, AST/ALT > 2.0, 
positive for hepatitis B surface antigen or hepatitis 
C antibody, presence of liver cirrhosis, and current use of 
aspirin (n=2,399). After these exclusions, 16,541 partici-
pants (8,074 men and 8,467 women) were included in the 
final analysis (Figure 1). Informed consent was obtained 
from each participant. This study was conducted in accor-
dance with the ethical principles of the Declaration of 
Helsinki and was approved by the Institutional Review 
Board of Yonsei University College of Medicine, Seoul, 
Korea (reference number: 3–2016-0051). The HERAS and 
HIRA datasets used in the current study are available from 
the corresponding author on reasonable request.
Data Collection
All participants completed a questionnaire about lifestyle 
and past medical history. Self-reported cigarette smok-
ing, alcohol consumption, and physical activity data 
were obtained from the questionnaires. Smoking status 
was categorized as nonsmoker or ex-smoker and current 
smoker. Regular alcohol consumption was defined as 
alcohol consumption ≥ 140 grams per week. 
Participants were asked about their physical exercise 
levels, and regular exercise was defined as physical 
activity of moderate intensity ≥ three times per week. 
Body weight and height were measured to the nearest 
0.1 kg and 0.1 cm, respectively, with participants in light 
indoor clothing without footwear. Body mass index 
(BMI) was calculated as the weight divided by the height 
squared (kg/m2). Systolic blood pressure and diastolic 
blood pressure were measured on the patient’s right 
arm with a standard mercury sphygmomanometer with 
the participant in a sitting position after 10 min of rest 
(Baumanometer, W.A. Baum Co Inc., Copiague, NY, 
USA). All blood samples were obtained from the ante-
cubital vein after overnight fasting for 12 h. FPG, total 
cholesterol, triglyceride, high density-lipoprotein choles-
terol (HDL-C), ALT, aspartate aminotransferase (AST), 
and γ-glutamyltransferase (GGT) were measured by 
enzymatic methods using a Hitachi 7600 automated 
chemistry analyzer (Hitachi Co., Tokyo, Japan). The 
hsCRP concentrations were measured with a Roche/ 
Hitachi 912 System (Roche Diagnostics, Indianapolis, 
IN, USA) using a latex-enhanced immunoturbidimetric 
method with a lower limit of detection of 0.09 mg/L. 
Hypertension was defined as systolic blood pressure ≥ 
140 mmHg, diastolic blood pressure ≥ 90 mmHg, or 
current use of hypertension medication. We calculated 
the hepatic steatosis index (HSI) score as follows: HSI 
score = 8 x ALT/AST ratio + BMI (kg/m2) (+ 2 if 
women). The cutoff value of the HSI score for NAFLD 
was defined as ≥ 36.15
Abdominal Ultrasonography
Liver ultrasonography was performed by experienced radi-
ologists blinded to laboratory and clinical data using 
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a 3.5-MHz transducer (HDI 5000, Philips, Bothell, WA, 
USA). Fatty liver was assessed semiquantitatively and 
described as absent (grade 0), mild (grade 1), mild to 
moderate (grade 2), moderate (grade 3), moderate to 
severe (grade 4), or severe (grade 5) based on hepatorenal 
echo contrast, liver brightness, deep attenuation, and vas-
cular blurring. Hepatic steatosis was defined as sonogra-
phically detected fatty liver (grade 1 to 5) without liver 
cirrhosis.
Outcomes
The study outcome assessed was IHD, which consisted of 
angina pectoris [International Classification of Diseases, 
10th revision (ICD-10) code I20] or acute myocardial 
infarction (ICD-10 code I21) that developed after initial 
study enrollment. To define baseline and postsurvey out-
comes, we linked a personal, 13-digit identification num-
ber that was assigned to each subject with Korea Health 
Insurance Review and Assessment (HIRA) service data, 
which is a repository of claims data collected in the pro-
cess of reimbursing healthcare providers, between 
November 2006 and December 2010.
Statistical Analysis
We defined elevated ALT within the normal range as 30–40 
IU/L in men and 23–40 IU/L in women, according to pre-
vious Korean epidemiological data.16 To assess the joint 
effects of hepatic steatosis and serum ALT on incident 
ischemic heart disease, we divided the study participants 
into four groups: no hepatic steatosis and controlled ALT 
(group 1), no hepatic steatosis and elevated ALT (group 2), 
hepatic steatosis and controlled ALT (group 3), and hepatic 
steatosis and elevated ALT (group 4). The baseline charac-
teristics of the participants in each group were compared 
using analysis of variance (ANOVA) for continuous vari-
ables and the chi-squared test for categorical variables. 
Kaplan–Meier curves were used to assess the cumulative 
incidence of ischemic heart disease. The Log rank test was 
used to determine whether the distributions of cumulative 
ischemic heart disease incidence differed among groups. 
After setting the first group as a reference group, the hazard 
ratios (HRs) and 95% confidence intervals (CIs) for IHD 
were calculated using multivariate Cox proportional hazards 
regression models after adjusting for potential confounding 
variables. Pairwise comparisons of receiver operating 
Total n=20,530 assessed for eligibility
Men (n=10,855), Women (n=9,675)
Excluded those having a history of ischemic heart disease or 
ischemic stroke or who were diagnosed with type 2 diabetes 
before, or met the diagnostic criteria for type 2 diabetes 
(n=1,590)
Participants without a history of 
ischemic heart disease or ischemic 
stroke or type 2 diabetes 
(n=18,940)
Excluded those who met one or more of the following 
criteria: less than 20 years old of age; ALT ≥ 40IU/L; 
AST/ALT > 2; positive for hepatitis B surface antigen or 
hepatitis C antibody; presence of liver cirrhosis; current use 
of aspirin (n=2,399) 
Total  16,541 participants were selected 
in the baseline study
Men (n= 8,074), Women (n= 8,467)
Figure 1 Flowchart for the selection of study participants.
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characteristic (ROC) curves were used to compare the area 
under the ROC curve (AUC) of IHD incidence based on 
hepatic steatosis with ALT, ALT classification, and NAFLD 
assessed by the HSI score. To assess the features of the joint 
effect, we compared the HR according to the presence of 
each one individually and both together among all partici-
pants. All analyses were performed using SAS version 9.4 
(SAS Institute Inc., Cary, NC, USA). All statistical tests were 
two-sided, and statistical significance was set at P < 0.05.
Results
Baseline Characteristics of Study 
Participants
Table 1 shows the baseline characteristics of the study 
population (n = 16,541; 8,074 men and 8,467 women) 
according to hepatic steatosis status and ALT. The mean 
age and BMI were 45.5 ± 10.7 years and 23.1 ± 2.9 kg/m2, 
respectively. The prevalence of hepatic steatosis and ele-
vated ALT was 28.7% and 13.7%, respectively.
The mean values of BMI, systolic blood pressure, 
diastolic blood pressure, FPG, total cholesterol, triglycer-
ide, and hsCRP were highest in the group with hepatic 
steatosis and elevated ALT (group 4), whereas the mean 
HDL-C levels were highest in the group with no hepatic 
steatosis and controlled ALT (group 1). The proportions of 
current smoking habit, hypertension, and NAFLD by HSI 
score were also highest in group 4.
Cumulative Ischemic Heart Disease 
Incidence
A total of 368 individuals (2.2%, 368/16,541) developed 
IHD during the follow-up period. Furthermore, group 4 
showed the highest cumulative incidences of ischemic 
heart disease up to 50 months after the baseline survey 
(Log rank test, P <0.001) (Figure 2). The incidence rates 
per 1000 person-years were 7.0, 11.4, 13.3, and 18.6 in the 
four groups.
Hazard Ratios for Incident Ischemic 
Heart Diseases
Table 2 shows the results of the multivariate Cox propor-
tional hazards regression analysis for the prediction of 
IHD according to hepatic steatosis and ALT. Compared 
with the referent first group, the HRs for IHD were 1.61 
(95% CI, 1.07–2.42) in the second group, 1.23 (95% CI, 
0.93–1.61) in the third group, and 1.81 (95% CI, 1.27–-
2.59) in the fourth group after adjusting for age, sex, BMI, 
smoking status, alcohol intake, and physical activity 
(Model 2, Figure 3). Similarly, these longitudinal positive 
associations were found after additionally adjusting for 
mean arterial pressure, FPG, HDL-C, triglycerides, γ- 
glutamyltransferase, and hsCRP (Model 3). The corre-
sponding adjusted HR for the fourth group versus the 
first group was 1.68 (95% CI, 1.16–2.42).
Comparison with Other Indicators of 
Liver Function
Using pairwise comparison of ROC analyses of incident 
IHD, the AUC of the groups classified according to hepa-
tic steatosis and ALT was significantly higher than the 
AUC of the group classified according to ALT and 
NAFLD assessed by the HSI score (P < 0.001, both). 
The AUC, sensitivity, and specificity of the groups accord-
ing to hepatic steatosis and ALT for classifying IHD were 
0.587, 51.1%, and 65.1%, respectively (Table 3). 
Furthermore, Figure 4 shows that the joint effect of hepatic 
steatosis and ALT has additive features.
Discussion
Among community-dwelling Korean adults without dia-
betes, we found that elevated ALT levels within the nor-
mal range were positively and independently associated 
with IHD incidence in this large-scale, prospective cohort 
study that included a 50-month follow-up. Our study 
showed that these associations persisted after further 
adjustment for lifestyle factors, inflammation and cardio-
metabolic markers, which was more prominent for indivi-
duals with the presence of hepatic steatosis.
We investigated the joint effect of hepatic steatosis and 
ALT levels within the normal range on the development of 
IHD among nondiabetic men and women. A previous 
cross-sectional study showed that hepatic steatosis was 
independently associated with subclinical coronary arterial 
calcification, regardless of classical cardiovascular risk 
factors such as insulin resistance and hypertension.17 In 
addition, the severity of hepatic steatosis was proportion-
ally associated with the degree of coronary 
atherosclerosis.18 Schindhelm et al also reported that 
ALT at baseline was prospectively related to coronary 
events independent of metabolic risk factors in a large 
cohort.19 Collectively, these studies suggested that both 
hepatic steatosis and ALT levels may be associated with 
a higher risk of CVD.
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Table 1 Baseline Characteristics of the Study Population
Variables Overall 
(n=16,541)
Group 1 Group 2 Group 3 Group 4 P value*
Control of 





Control of ALT + 
Hepatic Steatosis 
(n=3,573)





Age (years) 45.5 ± 
10.7
44.3 ± 10.8 45.6 ± 10.5 48.0 ± 10.2 47.9 ± 9.9 < 0.001 a,b,c,d, 
e
Male sex (%) 48.8 41.6 41.1 69.1 60.5 < 0.001 –
BMI (kg/m2) 23.1 ± 
2.9












74.0 ± 9.8 75.4 ± 10.0 79.3 ± 9.6 80.3 ± 9.7 < 0.001 a,b,c,d, 
e,f
AST (IU/L) 19.6 ± 
4.9
18.4 ± 4.0 26.0 ± 5.9 19.5 ± 4.1 25.1 ± 5.4 < 0.001 a,b,c,d, 
e,f
ALT (IU/L) 18.6 ± 
7.4
15.5 ± 5.0 30.5 ± 4.9 19.8 ± 5.4 32.3 ± 4.5 < 0.001 a,b,c,d, 
e,f
GGT (IU/L) 26.7 ± 
23.8
21.7 ± 17.3 40.7 ± 39.2 31.5 ± 22.7 45.0 ± 37.9 < 0.001 a,b,c,d, 
e,f
FPG (mg/dl) 91.0 ± 
9.7



















56.5 ± 12.7 55.3 ± 13.7 48.0 ± 10.3 47.9 ± 10.3 < 0.001 a,b,c,d, 
e








42.7 41.5 39.8 46.9 43.8 < 0.001 -
Regular 
exercise (%) #
32.0 32.6 30.6 31.1 30.2 0.151 -
Hypertension 
(%)




0.5 ± 1.0 0.0 ± 0.0 0.0 ± 0.0 1.6 ± 1.0 2.2 ± 1.3 < 0.001 b,c,d,e, 
f
(Continued)
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However, the joint effect of hepatic steatosis and ALT 
levels on ischemic heart disease has not been investigated 
in a prospective study. In multivariate Cox proportional 
hazards regression models, we found that elevation of ALT 
in response to fat accumulation in the liver was associated 
with coronary artery disease in a population-based cohort 
study. To our knowledge, this is the first study showing 
that an elevated ALT level, even within the normal range, 
could be a good predictor of IHD in patients with hepatic 
steatosis. Accordingly, patients with both hepatic steatosis 
and elevated ALT should be recommended to undergo an 
assessment of their IHD risk profile, even though their 
ALT is within the normal range.
NAFLD encompasses a spectrum of liver conditions 
ranging from simple steatosis to steatohepatitis and 
cirrhosis.20,21 Steatosis can progress to steatohepatitis and 
hepatic fibrosis.22 Although steatosis can be diagnosed by 
using noninvasive techniques such as ultrasound and 
Figure 2 Kaplan–Meier plots indicating the cumulative probability of being diagnosed with ischemic heart disease after the baseline survey.
Table 1 (Continued). 
Variables Overall 
(n=16,541)
Group 1 Group 2 Group 3 Group 4 P value*
Control of 





Control of ALT + 
Hepatic Steatosis 
(n=3,573)







14.0 4.2 27.3 23.8 60.5 < 0.001 -
Notes: *P values were calculated using 1-way ANOVA test or Pearson’s chi-square test; **Post hoc analysis with Bonferroni method for mean difference between groups: 
aGroup 1 versus Group 2; bGroup 1 versus Group 3, cGroup 1 versus Group 4; dGroup 2 versus Group 3; eGroup 2 versus Group 4, and fGroup 3 versus Group 4; 
***Alcohol intake ≥ 140 g/week; #Moderate intensity physical exercise ≥ three times/week; ##Average grade of hepatic steatosis via ultrasound. 
Abbreviations: BMI, body mass index; BP, blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, γ-glutamyltransferase; FPG, fasting plasma 
glucose; HDL-C, high density-lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein; NAFLD, nonalcoholic fatty liver disease; HSI, hepatic steatosis index.
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proton magnetic resonance spectroscopy (H-MRS), assess-
ment of fatty liver severity still requires a liver biopsy.23 In 
particular, steatohepatitis can only be diagnosed by liver 
biopsy. However, liver biopsy has limited applicability in 
clinical studies because of the risk related to the technique 
and uncertainty of the distribution of fatty infiltration. 
Therefore, serum ALT levels deserve particular attention 
because several studies have shown that ALT levels are 
proportionally correlated with hepatic steatosis.8 
Additionally, ALT is the most liver-specific enzyme 
among all liver enzymes. ALT often rises at some point 
after initial hepatic steatosis; thus, high-normal ALT may 
also represent a longer period of hepatic steatosis.24 
Overall, serum ALT levels can be a surrogate marker 
representing fatty infiltration and the severity of hepatic 
steatosis. In our studies, hepatic steatosis severity was 
significantly higher in those with high-normal ALT than 
in controls among individuals with hepatic steatosis. To 
elucidate the association between the severity of steatosis 
and the risk of IHD, this could be the best way to inves-
tigate the development of IHD in patients with steatosis 
and elevated serum ALT compared to subjects with neither 
characteristic or with only one hepatic manifestation. 
Furthermore, we excluded patients with abnormal ALT 
levels to investigate whether elevated ALT is a risk factor 
for IHD even when ALT falls within the normal range. We 
confirmed that elevated ALT could be a surrogate marker 
for IHD even when it falls within the normal range.
Some mechanisms may explain the significant relation-
ship between hepatic steatosis and IHD. First, insulin resis-
tance might be the reason hepatic steatosis and elevated ALT 
are associated with IHD. A recent study showed that elevated 
hepatic steatosis levels are proportionally correlated with 
insulin resistance in women.25 Hanley et al reported that 
serum ALT levels were associated with insulin resistance as 
measured directly in the Insulin Resistance Atherosclerosis 
Study.26 In states of insulin resistance, the antilipolytic effect 
of insulin decreases, causing an increase in free fatty acids 
(FFAs). The increase in FFAs induces lipotoxicity and liver 
fat accumulation.27 This relationship between IHD and hepa-
tic manifestations implicated fatty infiltration in the liver, 
which can lead to the release of proinflammatory adipocyto-
kines. Furthermore, these cytokines derived from adipocytes 
provide substrates for the formation of toxic metabolites and 
nonoxidative metabolic pathways, causing mitochondrial 
dysfunction.28,29 The inflammatory status accompanying 
Table 2 Hazard Ratios and 95% Confidence Intervals for New-Onset Ischemic Heart Diseases






Control of ALT + Hepatic 
Steatosis
Elevated ALT + Hepatic 
Steatosis
New cases of 
ischemic heart 
disease, n
180 30 109 49
Mean follow-up, 
years
2.4 ± 1.1 2.4 ± 1.0 2.3 ± 1.1 2.3 ± 1.1
Pearson-years of 
follow-up
25,435 2,635 8,226 2,638
Incidence rate/ 
1000 person -years



























1.14 (0.86–1.50) 1.68 (1.16–2.42) 0.016
Notes: Model 1, adjusted for age and sex; Model 2, adjusted for age, sex, body mass index, smoking status, alcohol intake, and physical activity; Model 3, adjusted for age, 
sex, body mass index, smoking status, alcohol intake, physical activity, mean arterial blood pressure, fasting plasma glucose, high density-lipoprotein cholesterol, triglycerides, 
γ-glutamyltransferase, and high sensitivity C-reactive protein level.
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reactive oxygen species could link the combination of hepa-
tosteatosis and elevated ALT to the risk of developing IHD. 
Schindhelm et al found that hepatic steatosis was associated 
with endothelial dysfunction assessed by brachial artery 
flow-mediated dilatation, independent of insulin 
resistance.10 When endothelial cells are damaged, circulating 
bone marrow-derived endothelial progenitor cells (EPCs) are 
responsible for regeneration of the endothelial monolayer.12 
However, patients with hepatic steatosis have low levels of 
EPCs, and decreased EPC levels can be correlated with 
endothelial dysfunction.30
Although there may be variance by laboratory, the 
upper limit of 40 IU/L is accepted as the normal range.12 
However, a recent Korean study has reported that 30 IU/L 
in men and 23 IU/L in women were the best cutoff values 
for the prediction of cardiometabolic health.31 In this 
study, elevated ALT, even in the normal range, could be 
an early indicator of IHD in patients with hepatic steatosis. 
Consistent with this finding, several studies have shown 
that a normal but elevated ALT level is a predictor of 
metabolic disturbances associated with hepatic steatosis.32
Some strengths and limitations require careful consid-
eration and may affect the interpretation of the results of 
the present study. A major strength of the work was that 
we conducted a prospective cohort study using a large 
number of Korean individuals linked to HIRA data derived 
from the universal coverage system in Korea. As a result, 
there was a very low chance that data were missing.33
Table 3 Hepatic Steatosis with ALT versus ALT Classification and NAFLD by HSI Score for Predicting Ischemic Heart Disease
Pairwise Comparison of AUC Ability to Classify IHD





Hepatic steatosis with ALT vs ALT classification 0.05 0.02 to 0.07 < 0.001
Hepatic steatosis with ALT vs NAFLD by HSI 
score
0.07 0.04 to 0.09 < 0.001
ALT classification vs NAFLD by HSI score 0.02 −0.01 to 
0.04
0.201
Hepatic steatosis with ALT 51.1 65.1 0.587 < 0.001
ALT classification 21.5 86.5 0.540 < 0.001
NAFLD by HSI score 18.5 86.2 0.523 0.023






Control of ALT Control of ALT
+ hepatic steatosis















Classification according to hepatic steatosis and ALT
P for trend = 0.003
Figure 3 Hazard ratios (95% CIs) for incident ischemic heart disease according to alanine aminotransferase and hepatic steatosis after adjusting for age, sex, body mass 
index, smoking status, alcohol intake, and physical activity.
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This study had some limitations that should also be 
acknowledged. First, although one study reported a day-by 
-day variation of up to 30% and diurnal variation,34 we 
evaluated the serum ALT levels only once and did not 
exclude those with excess alcohol consumption. However, 
we excluded subjects with viral hepatitis, such as hepatitis 
B and C, which may interfere with ALT levels, and we 
collected blood samples in the morning. Also, to minimize 
the inclusion of alcoholic steatohepatitis, we have 
excluded those with AST/ALT >2. Second, although 
biopsy is the gold standard for diagnosis, we did not use 
liver biopsy to assess NAFLD. However, ultrasound has 
been validated with reasonable sensitivity (greater than 
80%) and specificity (greater than 90%) in the clinical 
settings.35,36 Third, we may not fully take into considera-
tion possible underlying conditions affecting both ALT 
levels and IHD development, such as family history, sys-
temic inflammatory processes, or skeletal muscle mass. 
However, we performed multivariate Cox proportional 
hazards regression models after adjusting for confounding 
variables, including hsCRP, a systemic inflammatory mar-
ker. Hepatic steatosis combined with ALT, in addition to 
traditional cardiometabolic markers, may deserve an 
important consideration for the prediction of IHD, com-
parable to the HR for ever-smokers. Further studies are 
necessary to elucidate the role of muscle mass in the 
effects on incident IHD of hepatic steatosis combined 
with ALT within the normal range.
Conclusions
Hepatic steatosis and elevated ALT levels in the normal 
range jointly affect the development of IHD, independent 
of traditional CVD risk factors. Moreover, these joint 
effects were found to be a more powerful predictive indi-
cator of IHD than ALT alone or NAFLD assessed by HSI 
score alone. This implies that patients with steatosis and 
elevated ALT should be recommended to receive lifestyle 
advice and a comprehensive assessment of risk factors for 
IHD. More research is warranted to elucidate the patho-
physiological role of hepatic steatosis and ALT in the 
development of cardiovascular disease.
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